Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

January 31, 1998

Primary Completion Date

November 30, 2007

Study Completion Date

January 31, 2012

Conditions
Graft Versus Host DiseaseLeukemiaLymphomaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
Interventions
BIOLOGICAL

anti-thymocyte globulin

antithymocyte globulin IV for three days on days -3 to -1

DRUG

busulfan

If TBI is not tolerated, busulfan is substituted and administered orally every 6 hours for 4 days on days -8 to -5.

DRUG

cyclosporine

Cyclosporine begin on day -2 and continue for 6 months.

DRUG

melphalan

melphalan IV for three days on days -4 to -2

DRUG

methylprednisolone

Methylprednisolone IV for three days on days -3 to -1. Methylprednisolone begin on day -2 and continue for 6 months.

PROCEDURE

umbilical cord blood transplantation

On day 0, patients receive umbilical cord blood infusion.

RADIATION

radiation therapy

9 fractions of total body irradiation (TBI) on days -9 to -5

Trial Locations (1)

44106-5065

Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT00003335 - Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer | Biotech Hunter | Biotech Hunter